mProX™ Human TNFRSF9 Stable Cell Line

Product Information

Target Family

Oncology

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;MCF-7;ZR-75-30

Target Classification

Oncology Cell Lines

Target Research Area

Immunology Research

Related Diseases

Immunodeficiency 109 With Lymphoproliferation; B-Cell Lymphoma

Gene ID

Human:3604

UniProt ID

Human:Q07011

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

TNFRSF9, also known as CD137, is a member of the TNF receptor superfamily and is involved in immune responses. Research has shown that TNFRSF9 expression is higher in individuals with higher physical fitness levels, particularly in healthy individuals compared to those with type 2 diabetes. In mice, exercise training increased TNFRSF9 expression and enhanced mitochondrial content in subcutaneous adipose tissue. TNFRSF9 has also been associated with long-term disease severity in Parkinson's disease, with increased levels of TNFRSF9 correlating with more severe motor and cognitive symptoms. In autoimmune Addison's disease, altered biomarkers for cardiovascular disease and inflammation, including TNFRSF9, have been observed. Additionally, TNFRSF9 has been studied in the context of immunotherapy, as agonism of TNFRSF9 can enhance immune cell function and has been investigated as a potential treatment for cancer. TNFRSF9 stimulation has been shown to induce an inflammatory and immunosuppressive phenotype in neutrophils in ovarian cancer. Overall, TNFRSF9 has diverse applications in various disease contexts and immune responses.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human TNFRSF9 Stable Cell Line (S01YF-1023-PY233). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Cameron Jones (Verified Customer)

What is the role of TNFRSF9 in T cell signaling? Apr 04 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

TNFRSF9 is involved in organizing a signalosome in T cell membrane lipid microdomains, leading to the accumulation of PI3K and Akt, which are crucial for T cell receptor signaling. Apr 04 2020

chat Alex Davis (Verified Customer)

How does TNFRSF9 expression affect breast cancer? May 27 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

TNFRSF9 regulates cell proliferation, invasion, and apoptosis in breast cancer cells through the phosphorylation of p38, impacting the expression of PAX6, a gene involved in cancer progression. May 27 2022

Published Data

Fig.1 Cell proliferation was influenced by the expression of TNFRSF9.

A cell proliferation assay was carried out in MCF-7 cells, with transfections involving si-TNFRSF9 or pcDNA3.1-TNFRSF9, encompassing the utilization of both CCK-8 and BrdU assays. Similarly, within ZR-75-30 cells, a cell proliferation assay was performed, incorporating transfections of si-TNFRSF9 or pcDNA3.1-TNFRSF9, and encompassing the utilization of both CCK-8 and BrdU assays.

Ref: Liu, Xiaorong, et al. "TNFRSF9 Suppressed the Progression of Breast Cancer via the p38MAPK/PAX6 Signaling Pathway." Journal of oncology 2022 (2022).

Pubmed: 35799609

DOI: 10.1155/2022/8549781

Research Highlights

Bódis, Kálmán. et al. "Impact of physical fitness and exercise training on subcutaneous adipose tissue beiging markers in humans with and without diabetes and a high-fat diet-fed mouse model." Diabetes, obesity & metabolism, 2023.
This article discusses the effects of exercise training on inducing white adipose tissue (WAT) beiging and improving glucose homeostasis and mitochondrial function in rodents. It highlights the potential relevance of these findings for humans with type 2 diabetes. In particular, the relationship between physical fitness and beiging of subcutaneous WAT (scWAT) is examined in both healthy individuals and those with recent-onset type 2 diabetes. Additionally, a voluntary running wheel intervention is explored as a potential means of inducing beiging in mice.
Bódis, Kálmán. et al. "Impact of physical fitness and exercise training on subcutaneous adipose tissue beiging markers in humans with and without diabetes and a high-fat diet-fed mouse model." Diabetes, obesity & metabolism, 2023.
Pubmed: 37869933 DOI: 10.1111/dom.15322

H Hepp, Dagmar. et al. "Inflammatory Blood Biomarkers Are Associated with Long-Term Clinical Disease Severity in Parkinson's Disease." International journal of molecular sciences, 2023.
An altered immune response has been identified as a pathophysiological factor in Parkinson's disease (PD). The study aimed to identify blood immunity-associated proteins that discriminate PD from controls and are linked to long-term disease severity in PD patients. Using Proximity Extension Technology by OLINK, immune response-derived proteins in blood plasma were measured in a cohort of 66 PD patients and 52 age-matched healthy controls. In a subgroup of 30 PD patients, changes in protein levels were evaluated 7-10 years later and correlated with motor and cognitive assessments. Independent validation was conducted using data from the Parkinson's Disease Biomarkers Program (PDBP) and the Parkinson's Progression Markers Initiative (PPMI) cohorts. Results showed an altered immune response in PD patients compared to controls, identified by a panel of four proteins (IL-12B, OPG, CXCL11, and CSF-1). Five inflammation-associated proteins (CCL23, CCL25, TNFRSF9, TGF-alpha, and VEGFA) showed increased expression levels over time in PD and were partially associated with more severe motor and cognitive symptoms at follow-up. Additionally, increased CCL23 levels were linked to cognitive decline and motor symptom progression.
H Hepp, Dagmar. et al. "Inflammatory Blood Biomarkers Are Associated with Long-Term Clinical Disease Severity in Parkinson's Disease." International journal of molecular sciences, 2023.
Pubmed: 37834363 DOI: 10.3390/ijms241914915